Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use - Test2 - elhamkhani - TriplyDB

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

http://www.wikidata.org/entity/Q28193290

about

sameAs

Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American Co Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now?Upper gastrointestinal bleeding associated with antiplatelet drugs Peptic ulcer disease today Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study Preventing recurrent ulcer bleeding. Switch from acetylsalicylic acid to clopidogrel or add esomeprazole?Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000 Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies My health: whose responsibility? Low-dose aspirin and older people Should we eradicate Helicobacter pylori in non-steroidal anti-inflammatory drug users?Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin Should we eradicate Helicobacter pylori infection in patients receiving nonsteroidal anti-inflammatory drugs or low-dose aspirin?The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease Optimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study.Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks.Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Risk factors and therapeutic response in Chinese patients with peptic ulcer disease.Effect of a Proton Pump Inhibitor on Tumor Bleeding Prevention in Unresectable Gastric Cancer Patients: a Double-Blind, Randomized, Placebo-Controlled Trial

P2860

Q22241289-BBA450D8-E341-43AB-8EAE-CE2771D45BF8 Q22241777-E3DE597D-ADD0-41D5-8E7A-BCCC72A0482B Q24674636-CE3EEE49-A17F-4822-BAB3-0891C522F06B Q26749687-4C1B6AF6-A69E-47E1-82EE-84B04E1246B7 Q26995752-0499A6D1-17DB-4D04-9346-55A57C0CAAD1 Q27004834-B112C99C-DF26-436D-9E82-8B7F5A909AEE Q27027977-0FA9524B-1BE2-4740-819C-740FECF8C7B6 Q28166768-08E287F1-93DA-4A77-97B7-3C2CC8D2F894 Q28168123-41F5E963-1AB8-49C6-865A-44AC00F10717 Q28176840-F03623F0-9DA3-4CF4-8DC9-D9926FD60E14 Q28182449-2FAE8DCC-7869-423F-BD6A-24DBE5B03C15 Q28186823-1BF4B917-4434-4C98-B905-72EAC9CF0812 Q28191928-1A3F56ED-6BB1-46D7-8BE1-5DDA609472ED Q28192701-A8873DAC-FFE0-4DF6-A8D0-788A434A6CFB Q28193564-52328B3C-CDE5-45DA-A56D-33B3D0EAA1B8 Q28194354-9A80C1C0-AB4E-4BE0-8232-5E84D742BFBA Q28194844-7BC40922-5039-480F-A351-E6469EEB0900 Q28195079-B7EF9F5A-4B47-4ED8-9D40-E4AFE621ABE8 Q28195971-BC80A95B-ECC9-45AD-81FD-FFEAB99715FA Q28196518-262CAEBB-E64B-40AE-B1F2-9266C4090941 Q28196797-D923DC46-3BDB-4C94-9521-C8788F31CED9 Q28196810-61C6E8A0-F4DB-4096-A52E-99225CB796F0 Q28196933-ABA4E6F6-4B8B-4A97-BC52-1351326FD638 Q28198718-12A66CC9-20D2-46AE-A8A5-10A476BE3BE9 Q28200569-2D36654E-8A04-4CEE-B83E-7A7C4AF64896 Q28201631-AFCA61C2-F772-43F9-9BB7-7911146B4313 Q28211894-45DF6C76-2CC2-4B2E-962C-1F9A7F4AA90A Q28212423-B7B3094C-B163-455D-9B34-C86365FC09F7 Q28213638-2B93646A-CC7F-48EF-8D7D-9E5B01A9E4AD Q28217400-B4CB7C35-76DB-4539-B8CA-0DB22E3B1E49 Q28218326-2C43F6B4-5F44-4B33-ACDD-814B163FB995 Q28218738-50091883-BA52-480F-8DBE-463E12D7F45C Q28219972-8621671B-D9E7-491A-BD57-86DBC9F1A8F9 Q30457290-639911EA-C5EF-4D77-94CD-F54051F8619A Q33583991-664662BC-4163-4DBB-88AD-88FD6E392EEC Q33647298-E6A1B21C-5A74-4AB8-8F7D-9EC83E37C8F0 Q33678007-B3CC37C8-554A-4027-9194-37BE0EEB5982 Q33698340-E6D9A0A1-2770-40A5-A421-D7D0451247EF Q33812202-60B41A55-AA38-423C-8095-AEF80A8EB4C4 Q33849286-6B34E792-F178-451E-AB47-E7C7E02F147E

P2860

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

http://www.wikidata.org/entity/Q28193290

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@ast

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@en

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@nl

type

label

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@ast

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@en

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@nl

prefLabel

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@ast

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@en

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@nl

P1433

Q28193290-AC2B44E8-D1CA-40AB-B18B-01E5DA43A878

P1476

Q28193290-5C53CA5E-146F-49DC-99E7-003414C40055

P2093

Q28193290-23F53EBB-7045-4A1C-9343-9AD98D2C22ED

Q28193290-5AB3879E-BB44-4EBF-A5EF-C3EC84E102BD

Q28193290-75E67EBC-1D46-4CCD-9214-F9FC58766746

Q28193290-A433D572-948C-4D6F-B910-1D442A5D13B5

Q28193290-AF314686-AFFD-441E-8AC9-75232ECC3C46

Q28193290-B388ED2C-EECC-47D0-9FD8-B510531C10C4

Q28193290-B6FA5086-A420-4953-86FF-60DDF44D0779

Q28193290-C051289B-801B-4454-8FFA-2F3EA7B3A2E2

Q28193290-CBCD3DFD-8FD6-4A31-A7DA-1A4D69A59CF1

Q28193290-D23475EF-9339-4A9B-A3FB-64EC16013EC8

P304

Q28193290-CB4E820B-D248-4519-B8DE-8361EAA0992E

P31

Q28193290-0B84AFD8-EBBE-48C5-BE81-EF50F80818C3

P3181

Q28193290-B67BFBB7-7751-4480-87C6-2639B5EDFBD7

P356

Q28193290-C886D111-F376-4F6A-BEBA-68D53317DAC6

P407

Q28193290-BC51B527-B6E9-4FEC-82E7-E31521097687

P433

Q28193290-BB037195-EDDC-4FAA-B3F8-0494C35691CB

P478

Q28193290-02C97841-7D80-494F-A643-D1D3EE7FA866

P577

Q28193290-E60736E9-8FC1-4EEB-A398-DAAD531C7AE1

P698

Q28193290-8A9B7D07-CDAF-42F8-9F5D-29A37C97C8D5

P921

Q28193290-E517C4BB-BDBA-4C5A-AFDB-758DBA33EAC4

P3181

P356

P1433

The New England Journal of Medicine

P1476

Lansoprazole for the preventio ...... long-term low-dose aspirin use

@en

P2093

Annie O O Chan

http://www.w3.org/2001/XMLSchema#string

Benjamin C Y Wong

http://www.w3.org/2001/XMLSchema#string

Ching Lung Lai

http://www.w3.org/2001/XMLSchema#string

George K K Lau

http://www.w3.org/2001/XMLSchema#string

John Wong

http://www.w3.org/2001/XMLSchema#string

Kam Chuen Lai

http://www.w3.org/2001/XMLSchema#string

Kent Man Chu

http://www.w3.org/2001/XMLSchema#string

Man Fung Yuen

http://www.w3.org/2001/XMLSchema#string

Shiu Kum Lam

http://www.w3.org/2001/XMLSchema#string

Wai Man Wong

http://www.w3.org/2001/XMLSchema#string

P304

2033-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3951080

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA012877

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

346

http://www.w3.org/2001/XMLSchema#string

P577

2002-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12087138

http://www.w3.org/2001/XMLSchema#string

P921